BRISTOL-MYERS SQUIBB CO

Explore how Bristol‑Myers Squibb’s diverse portfolio positions it to tap the growing autoimmune uveitis market, with insights on market trends, valuation, and future opportunities.

BCG

UBS sees Bristol‑Myers Squibb as a $80 target with dividend income, but oncology’s checkpoint‑inhibitor resistance and uncertain trials keep upside under scrutiny.

Explore BMY’s $2.3B Texas expansion—boosting biopharma capacity, job creation, and supply chain resilience, while weighing investment risks and market dynamics.

Explore Bristol‑Myers Squibb’s latest merger buzz with AstraZeneca, FDA‑approved skin‑cancer partnership, and market insights—why investors should watch BMY now.

Stock‑market update: Bristol‑Myers Squibb shares rise to $57.52 as analysts warn of possible overvaluation despite strong performance.

Explore Bristol‑Myers Squibb’s latest 3.9% stock surge, its strong oncology pipeline, and the booming radioligand therapy market—insights for investors in 2026.

Explore Bristol‑Myers Squibb’s strategic growth: institutional confidence, mental‑health partnership, and solid market outlook—why BMY stands out in biopharma.

Raymond James keeps Bristol‑Myers Squibb at “Market Perform,” citing steady $59 price, solid guidance, and solid valuation—stable play for pharma‑sector investors.

UBS lifts Bristol‑Myers Squibb’s target price ahead of Milvexian data, boosting investor outlook on its anticoagulant pipeline and potential growth.